Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia

被引:155
作者
Choudhary, Pratik [1 ]
Rickels, Michael R. [2 ]
Senior, Peter A. [3 ]
Vantyghem, Marie-Christine [4 ]
Maffi, Paola [5 ]
Kay, Thomas W. [6 ]
Keymeulen, Bart [7 ,8 ]
Inagaki, Nobuya [9 ,10 ]
Saudek, Frantisek [11 ]
Lehmann, Roger [12 ]
Hering, Bernhard J. [13 ,14 ]
机构
[1] Kings Coll London, Diabet Res Grp, London, England
[2] Univ Penn, Perelman Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA USA
[3] Univ Alberta, Dept Med, Div Endocrinol, Edmonton, AB, Canada
[4] Lille Univ Hosp, Dept Endocrinol & Metab, INSERM U1190, European Genom Inst Diabet, Lille, France
[5] Sci Inst Osped San Raffaele, Diabet Res Inst, Milan, Italy
[6] Univ Melbourne, Immunol & Diabet Unit, St Vincents Inst, Melbourne, Australia
[7] Vrije Univ Brussel, Diabet Clin, Brussels, Belgium
[8] Vrije Univ Brussel, Res Ctr, Brussels, Belgium
[9] Kyoto Univ, Dept Diabet, Kyoto, Japan
[10] Kyoto Univ, Clin Nutr, Kyoto, Japan
[11] Inst Clin & Expt Med, Ctr Diabet, Prague, Czech Republic
[12] Univ Zurich, Dept Endocrinol & Diabetol, Zurich, Switzerland
[13] Univ Minnesota, Schulze Diabet Inst, Minneapolis, MN 55455 USA
[14] Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA
基金
美国国家卫生研究院; 英国医学研究理事会;
关键词
INTENSIVE INSULIN THERAPY; PANCREAS-KIDNEY TRANSPLANTATION; GLUCOSE MONITORING-SYSTEM; SIMULTANEOUS ISLET-KIDNEY; CELL SECRETORY CAPACITY; BASAL-BOLUS TREATMENT; GLYCEMIC CONTROL; IMPAIRED AWARENESS; PUMP THERAPY; OPEN-LABEL;
D O I
10.2337/dc15-0090
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Problematic hypoglycemia, defined as two or more episodes per year of severe hypoglycemia or as one episode associated with impaired awareness of hypoglycemia, extreme glycemic lability, or major fear and maladaptive behavior, is a challenge, especially for patients with long-standing type 1 diabetes. Individualized therapy for such patients should include a composite target: optimal glucose control without problematic hypoglycemia. Therefore, we propose a tiered, four-stage algorithm based on evidence of efficacy given the limitations of educational, technological, and transplant interventions. All patients with problematic hypoglycemia should undergo structured or hypoglycemia-specific education programs (stage 1). Glycemic and hypoglycemia treatment targets should be individualized and reassessed every 3-6 months. If targets are not met, one diabetes technology-continuous subcutaneous insulin infusion or continuous glucose monitoring-should be added (stage 2). For patients with continued problematic hypoglycemia despite education (stage 1) and one diabetes technology (stage 2), sensor-augmented insulin pumps preferably with an automated low-glucose suspend feature and/or very frequent contact with a specialized hypoglycemia service can reduce hypoglycemia (stage 3). For patients whose problematic hypoglycemia persists, islet or pancreas transplant should be considered (stage 4). This algorithm provides an evidence-informed approach to resolving problematic hypoglycemia; it should be used as a guide, with individual patient circumstances directing suitability and acceptability to ensure the prudent use of technology and scarce transplant resources. Standardized reporting of hypoglycemia outcomes and inclusion of patients with problematic hypoglycemia in studies of new interventions may help to guide future therapeutic strategies.
引用
收藏
页码:1016 / 1029
页数:14
相关论文
共 109 条
[1]   Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes [J].
Ang, Meidjie ;
Meyer, Christian ;
Brendel, Mathias D. ;
Bretzel, Reinhard G. ;
Linn, Thomas .
DIABETOLOGIA, 2014, 57 (03) :623-632
[2]   Hypoglycemia in the diabetes control and complications trial [J].
不详 .
DIABETES, 1997, 46 (02) :271-286
[3]   PANCREAS TRANSPLANTATION IN DIABETIC HUMANS NORMALIZES HEPATIC GLUCOSE-PRODUCTION DURING HYPOGLYCEMIA [J].
BARROU, Z ;
SEAQUIST, ER ;
ROBERTSON, RP .
DIABETES, 1994, 43 (05) :661-666
[4]   Improvement in Outcomes of Clinical Islet Transplantation: 1999-2010 [J].
Barton, Franca B. ;
Rickels, Michael R. ;
Alejandro, Rodolfo ;
Hering, Bernhard J. ;
Wease, Stephen ;
Naziruddin, Bashoo ;
Oberholzer, Jose ;
Odorico, Jon S. ;
Garfinkel, Marc R. ;
Levy, Marlon ;
Pattou, Francois ;
Berney, Thierry ;
Secchi, Antonio ;
Messinger, Shari ;
Senior, Peter A. ;
Maffi, Paola ;
Posselt, Andrew ;
Stock, Peter G. ;
Kaufman, Dixon B. ;
Luo, Xunrong ;
Kandeel, Fouad ;
Cagliero, Enrico ;
Turgeon, Nicole A. ;
Witkowski, Piotr ;
Naji, Ali ;
O'Connell, Philip J. ;
Greenbaum, Carla ;
Kudva, Yogish C. ;
Brayman, Kenneth L. ;
Aull, Meredith J. ;
Larsen, Christian ;
Kay, Tom W. H. ;
Fernandez, Luis A. ;
Vantyghem, Marie-Christine ;
Bellin, Melena ;
Shapiro, A. M. James .
DIABETES CARE, 2012, 35 (07) :1436-1445
[5]   Impact of Islet Transplantation on Diabetes Complications and Quality of Life [J].
Bassi, Roberto ;
Fiorina, Paolo .
CURRENT DIABETES REPORTS, 2011, 11 (05) :355-363
[6]   Potent Induction Immunotherapy Promotes Long-Term Insulin Independence After Islet Transplantation in Type 1 Diabetes [J].
Bellin, M. D. ;
Barton, F. B. ;
Heitman, A. ;
Harmon, J. V. ;
Kandaswamy, R. ;
Balamurugan, A. N. ;
Sutherland, D. E. R. ;
Alejandro, R. ;
Hering, B. J. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (06) :1576-1583
[7]   Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia [J].
Bergenstal, Richard M. ;
Klonoff, David C. ;
Garg, Satish K. ;
Bode, Bruce W. ;
Meredith, Melissa ;
Slover, Robert H. ;
Ahmann, Andrew J. ;
Welsh, John B. ;
Lee, Scott W. ;
Kaufman, Francine R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (03) :224-232
[8]   Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes [J].
Bergenstal, Richard M. ;
Tamborlane, William V. ;
Ahmann, Andrew ;
Buse, John B. ;
Dailey, George ;
Davis, Stephen N. ;
Joyce, Carol ;
Peoples, Tim ;
Perkins, Bruce A. ;
Welsh, John B. ;
Willi, Steven M. ;
Wood, Michael A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (04) :311-320
[9]   Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial [J].
Bode, B. W. ;
Buse, J. B. ;
Fisher, M. ;
Garg, S. K. ;
Marre, M. ;
Merker, L. ;
Renard, E. ;
Russell-Jones, D. L. ;
Hansen, C. T. ;
Rana, A. ;
Heller, S. R. .
DIABETIC MEDICINE, 2013, 30 (11) :1293-1297
[10]  
Broers S, 2005, NETH J MED, V63, P164